Literature DB >> 15198132

Haloperidol in palliative care.

Jane Vella-Brincat1, A D Macleod.   

Abstract

Haloperidol is one of 20 'essential' medications in palliative care. Its use is widespread in palliative care patients. The pharmacology of haloperidol is complex and the extent and severity of some of its adverse effects, particularly extrapyramidal adverse effects (EPS), may be related to the route of administration. Indications for the use of haloperidol in palliative care are nausea and vomiting and delirium. Adverse effects include EPS and QT prolongation. Sedation is not a common adverse effect of haloperidol. It is important that palliative care practitioners have a comprehensive understanding of the indications, doses, adverse effects and pharmacology of haloperidol. This review is intended to address these issues.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15198132     DOI: 10.1191/0269216304pm881oa

Source DB:  PubMed          Journal:  Palliat Med        ISSN: 0269-2163            Impact factor:   4.762


  10 in total

1.  In-hospital cardiac arrest is associated with use of non-antiarrhythmic QTc-prolonging drugs.

Authors:  Marie L De Bruin; Pim N J Langendijk; Richard P Koopmans; Arthur A M Wilde; Hubert G M Leufkens; Arno W Hoes
Journal:  Br J Clin Pharmacol       Date:  2006-07-21       Impact factor: 4.335

Review 2.  Treating an established episode of delirium in palliative care: expert opinion and review of the current evidence base with recommendations for future development.

Authors:  Shirley H Bush; Salmaan Kanji; José L Pereira; Daniel H J Davis; David C Currow; David Meagher; Kiran Rabheru; David Wright; Eduardo Bruera; Michael Hartwick; Pierre R Gagnon; Bruno Gagnon; William Breitbart; Laura Regnier; Peter G Lawlor
Journal:  J Pain Symptom Manage       Date:  2014-01-28       Impact factor: 3.612

3.  Pain Management and Symptom-Oriented Drug Therapy in Palliative Care.

Authors:  Carsten Klein; Ute Lang; Johannes Bükki; Reinhard Sittl; Christoph Ostgathe
Journal:  Breast Care (Basel)       Date:  2011-02-22       Impact factor: 2.860

4.  Adverse events of opioids for cancer-related pain in a resource-limited setting: a cross-sectional study from Sudan.

Authors:  Moawia Mohammed Ali Elhassan; Amal Abdulbagi Abdulfatah Mohammed; Amnah Abdulazeem Omer; Arafa Ahmed Mohammed Azeem; Hiba Mohammed Abdelkfi Mohammed; Isra Elameen Mustafa Ibrahim; Nashwa Abdelaziz Abdelrheem Ahmed
Journal:  Ecancermedicalscience       Date:  2022-03-24

Review 5.  Nausea and Vomiting: a Palliative Care Imperative.

Authors:  Rita J Wickham
Journal:  Curr Oncol Rep       Date:  2020-01-20       Impact factor: 5.075

6.  Pharmacovigilance in hospice/palliative care: net effect of haloperidol for delirium.

Authors:  Gregory B Crawford; Meera Agar M; Stephen J Quinn; Jane Phillips; Caroline Litster; Natasha Michael; Matthew Doogue; Debra Rowett; David C Currow
Journal:  J Palliat Med       Date:  2013-10-18       Impact factor: 2.947

7.  Medication use during end-of-life care in a palliative care centre.

Authors:  Anniek D Masman; Monique van Dijk; Dick Tibboel; Frans P M Baar; Ron A A Mathôt
Journal:  Int J Clin Pharm       Date:  2015-04-09

Review 8.  Clinical Assessment and Management of Delirium in the Palliative Care Setting.

Authors:  Shirley Harvey Bush; Sallyanne Tierney; Peter Gerard Lawlor
Journal:  Drugs       Date:  2017-10       Impact factor: 9.546

9.  Physicians' experiences and perspectives regarding the use of continuous sedation until death for cancer patients in the context of psychological and existential suffering at the end of life.

Authors:  Livia Anquinet; J Rietjens; A van der Heide; Sophie Bruinsma; Rien Janssens; Luc Deliens; Julia Addington-Hall; W Henry Smithson; Jane Seymour
Journal:  Psychooncology       Date:  2013-12-05       Impact factor: 3.894

10.  Solid lipid nanoparticles for nose to brain delivery of haloperidol: in vitro drug release and pharmacokinetics evaluation.

Authors:  Mohd Yasir; Udai Vir Singh Sara
Journal:  Acta Pharm Sin B       Date:  2014-11-21       Impact factor: 11.413

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.